ReviewCurrent drug targets2012
Targeting CSC-related miRNAs for cancer therapy by natural agents.
Review in Current drug targets, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 50 citations in OpenAlex.
- Polyphenol-Enriched Blueberry Preparation Controls Breast Cancer Stem Cells by Targeting FOXO1 and miR-145.Molecules (Basel, Switzerland) · 2021Article
- Morusin inhibits the growth of human colorectal cancer HCT116‑derived sphere‑forming cells via the inactivation of Akt pathway.International journal of molecular medicine · 2021Article
- The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment.Cancer cell international · 2021Review
- Involvement of Non-Coding RNAs in Chemo- and Radioresistance of Nasopharyngeal Carcinoma.Cancer management and research · 2021Review
- MiRNAs in Radiotherapy Resistance of Nasopharyngeal Carcinoma.Journal of Cancer · 2020Review
- Nutraceutical Targeting of Inflammation-Modulating microRNAs in Severe Forms of COVID-19: A Novel Approach to Prevent the Cytokine Storm.Frontiers in pharmacology · 2020Review
- Honokiol Suppressed Pancreatic Cancer Progression via miR-101/Mcl-1 Axis.Cancer management and research · 2020Article
- Cell Cycle Regulation of Stem Cells by MicroRNAs.Stem cell reviews and reports · 2018Review
- MicroRNA-30b targets Snail to impede epithelial-mesenchymal transition in pancreatic cancer stem cells.Journal of Cancer · 2018Article
- MicroRNA signature in the chemoprevention of functionally-enriched stem and progenitor pools (FESPP) by Active Hexose Correlated Compound (AHCC).Cancer biology & therapy · 2017Article
- Curcumin induces G2/M arrest, apoptosis, NF-κB inhibition, and expression of differentiation genes in thyroid carcinoma cells.Journal of cancer research and clinical oncology · 2017Article
- Review
- Cross-Kingdom Regulation of Putative miRNAs Derived from Happy Tree in Cancer Pathway: A Systems Biology Approach.International journal of molecular sciences · 2017Article
- Overexpression of microRNA-21 strengthens stem cell-like characteristics in a hepatocellular carcinoma cell line.World journal of surgical oncology · 2016Article
- Sirolimus induces apoptosis and reverses multidrug resistance in human osteosarcoma cells in vitro via increasing microRNA-34b expression.Acta pharmacologica Sinica · 2016Article
- Novel Holistic Approaches for Overcoming Therapy Resistance in Pancreatic and Colon Cancers.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2016Review
- Review
- Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer.Oncotarget · 2014Review
- Apoptotic death of cancer stem cells for cancer therapy.International journal of molecular sciences · 2014Review
- Epigenetic regulation of miRNA-cancer stem cells nexus by nutraceuticals.Molecular nutrition & food research · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
The theory of cancer stem cells (CSCs) has provided evidence on fundamental clinical implications because of the involvement of CSCs in cell migration, invasion, metastasis, and treatment resistance, which leads to the poor clinical outcome of cancer patients. Therefore, targeting CSCs will provide a novel therapeutic strategy for the treatment and/or prevention of tumors. However, the regulation of CSCs and its signaling pathways during tumorigenesis are not well understood. MicroRNAs (miRNAs) have been proved to act as key regulators of the post-transcriptional regulation of genes, which involve in a wide array of biological processes including tumorigenesis. The altered expressions of miRNAs are associated with poor clinical outcome of patients diagnosed with a variety of tumors. Therefore, emerging evidence strongly suggest that miRMAs play critical roles in tumor development and progression. Emerging evidence also suggest that miRNAs participate in the regulation of tumor cell growth, migration, invasion, angiogenesis, drug resistance, and metastasis. Moreover, miRNAs such as let-7, miR-21, miR-22, miR-34, miR-101, miR-146a, and miR-200 have been found to be associated with CSC phenotype and function mediated through targeting oncogenic signaling pathways. In this article, we will discuss the role of miRNAs in the regulation of CSC phenotype and function during tumor development and progression. We will also discuss the potential role of naturally occurring agents (nutraceuticals) as potent anti-tumor agents that are believed to function by targeting CSC-related miRNAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.